Evidence map›Paper›PMID 40418439›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025

RIPK1: A Promising Target for Intervention Neuroinflammation.

Feixing Yan, Yujun Qiao, Shunli Pan, Anjuan Kang, Haile Chen, Yinliang Bai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feixing YanSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, China.
Yujun QiaoDepartment of Pharmacy, Lanzhou University Second Hospital, Lanzhou, 730000, China.
Shunli PanDepartment of Pharmacy, Lanzhou University Second Hospital, Lanzhou, 730000, China.
Anjuan KangSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, China.
Haile ChenDepartment of Pharmacy, Lanzhou University Second Hospital, Lanzhou, 730000, China.
Yinliang BaiSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, China. ylb@lzu.edu.cn.

Funding

China Foundation for International Medical Exchanges (23)0207China Health Promotion Foundation (23)1263the "Cuiying Science and Technology Program" of the Second Hospital of Lanzhou University CY2023-QN-B03the Natural Science Foundation of Gansu Province 24JRRA346
6 · The paper itself

Abstract

Necroptosis is a novel mode of cell death that differs from traditional apoptosis, characterized by distinct molecular mechanisms and physiopathological features. Recent research has increasingly underscored the pivotal role of necroptosis in various neurological diseases, including stroke, Alzheimer's disease and multiple sclerosis. A defining hallmark of these conditions is neuroinflammation, a complex inflammatory response that critically influences neuronal survival. This review provides a comprehensive analysis of the mechanistic underpinnings of necroptosis and its intricate interplay with neuroinflammation, exploring the interrelationship between the two processes and their impact on neurological disorders. In addition, we discuss potential therapeutic strategies that target the intervention of necroptosis and neuroinflammation, offering novel avenues for intervention. By deepening our understanding of these interconnected processes, the development of more effective treatments approaches holds significant promise for improving patient outcomes in neurological disorders.

Indexed as

NecroptosisNeuroinflammatory DiseasesReceptor-Interacting Protein Serine-Threonine KinasesAnimalsHumansReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanNecroptosisNeuroinflammationRIPK1RIPK1 inhibitor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.